Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H30F3N3O4 |
| Molecular Weight | 493.5186 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CC1=CC(C(N)=O)=C2N(CCCO)C=CC2=C1)NCCOC3=CC=CC=C3OCC(F)(F)F
InChI
InChIKey=VICSLOHTZDWOFF-QGZVFWFLSA-N
InChI=1S/C25H30F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-7,10,14-15,17,30,32H,4,8-9,11-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
KMD-3241 (Dehydro Silodosin) is a silodosin metabolite (also known as an impurity of Silodosin). Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical and approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia. The affnities of silodosin metabolites, KMD-3241, KMD-3289 and
KMD-3295, for alpha1A-AR subtype receptor were equal to or lower than that of silodosin.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9891871
Created by
admin on Sat Dec 16 10:48:16 GMT 2023 , Edited by admin on Sat Dec 16 10:48:16 GMT 2023
|
PRIMARY | |||
|
6787MV7QU0
Created by
admin on Sat Dec 16 10:48:16 GMT 2023 , Edited by admin on Sat Dec 16 10:48:16 GMT 2023
|
PRIMARY | |||
|
DTXSID20432445
Created by
admin on Sat Dec 16 10:48:16 GMT 2023 , Edited by admin on Sat Dec 16 10:48:16 GMT 2023
|
PRIMARY | |||
|
175870-21-0
Created by
admin on Sat Dec 16 10:48:16 GMT 2023 , Edited by admin on Sat Dec 16 10:48:16 GMT 2023
|
PRIMARY |
PARENT (METABOLITE)
SUBSTANCE RECORD
